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doi:10.1016/j.ejvs.2010.02.026Abstract Objectives: There have been few randomised studies comparing Radiofrequency
Ablation(RFA) with other endovenous techniques. The primary aim of this study was to deter-
mine whether RFA of the great saphenous vein (GSV) was associated with less pain and bruising
than endovenous laser ablation (EVLA).
Materials and methods: This trial had two cohorts e patients with bilateral GSV incompetence
causing varicose veins (VV) and those with unilateral GSV VVs. In total 87 legs were treated in
this study. Limbs in the bilateral group were treated with RFA in one leg and EVLA in the other.
In the unilateral group limbs were randomised to RFA or EVLA. RFA was performed using the
Celon RFiTT system (Teltow, Germany). EVLA was performed using an 810 nm Laser (Biolitec
AG, Germany). Phlebectomies were performed as required. Primary endpoints were patient as-
sessed pain and bruising measured by visual analogue scale (VAS). Secondary endpoints were
patency assessed by duplex ultrasound at 6 weeks and 6 months.
Results: In the bilateral group, RFA resulted in significantly less pain than EVLA on days 2e11
postoperatively. RFA also resulted in significantly less bruising than EVLA on days 3e9. There
were no significant differences in mean post operative pain, bruising and activity scores in
the unilateral group. Both RFA and EVLA resulted in occlusion rates of 95% at 10 days postop-
eratively.
Conclusions: RFAwas less painful for patients than EVLA and produced less bruising in the postop-
erative period with comparable success rates but there was no difference in the unilateral group.
ª 2009 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.@nhs.net (B.D. Braithwaite).
lsevier Ltd on behalf of European Society for Vascular Surgery.
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The development of minimally invasive procedures for the
treatment of varicose veins has been led by a desire to
reduce operative trauma and bruising associated with
standard surgical techniques.1 Currently there are two
major thermal endovenous treatments available; Endove-
nous Laser Ablation (EVLA) and Radiofrequency Ablation
(RFA). Randomised clinical trials comparing EVLA with
surgery have shown EVLA to be an equally effective treat-
ment, while producing less pain and bruising and a signifi-
cantly better quality of life.2e4 Randomised studies
comparing RFA and open surgery showed that RFA caused
less pain, bruising and fewer complications with less time
off work.5e9
At the time of designing our study, the comparative
advantages of RFA and EVLA with an 810 nm laser had not
been assessed. The primary aim of this study was to
determine whether RFA of the GSV was associated with less
pain and brusing than EVLA. The secondary aims were to
assess efficacy of vein ablation and quality of life following
these procedures.
Methods
Patients who presented at the Department of Vascular and
Endovascular Surgery at University Hospital Nottingham
with bilateral or unilateral varicose veins between March
2006 and December 2007 were considered for inclusion in
this study. Each patient had a pre-operative duplex ultra-
sound examination to identify the site of reflux and suit-
ability for endovenous ablation.10 Ultrasonography was
performed by two vascular technologists using GE Logic 9
scanners (General Electric ultrasound, Milwaukee,USA).
Two cohorts of patients were studied: patients with bilat-
eral varicose veins (BLARA study) and patients with unilat-
eral varicose veins (ULARA study). All participants gave
written informed consent, and the study was approved by
the hospital research and development department and
Research Ethics Committee.
Inclusion and exclusion criteria
Guidelines for inclusion on duplex criteria included a GSV
without significant tortuosity or with a diameter less than
12 mm lying in the saphenous compartment and not a more
superficial tributary. Veins had to be free of current or
previous thrombophlebitis. Patients who were on antico-
agulants, who had pacemakers, concomitant peripheral
artery disease or serious systemic disease were excluded.
All patients had to have venous disease which was Clinical
grades 2e6, primary (Ep), Superficial (As) and reflux only
(Pr).
Randomisation was performed preoperatively using
random number generator. For the BLARA study the left leg
was randomised to one treatment with their right leg
assigned to the other. Patients presenting with unilateral
varicose veins were randomised to either RFA or EVLA for
the affected limb (ULARA study). Patients were not advised
of the treatment allocation so ensure that this trial was
carried out in a blinded fashion, as far as was possible. Alloperations for the BLARA study were carried out in the Day
Surgery Unit, City Hospital, Nottingham and were per-
formed under general anaesthetic by the same surgeon.
History and consent were taken from the patient and the
veins marked with a pen. The CEAP classification was
assigned by a surgeon skilled in the management of venous
disease. Patients were asked to complete the Aberdeen
Varicose Vein Questionnaire (AVVQ) preoperatively. This
has been shown to be a valid measure of quality of life for
patients with varicose veins.11e13 Treatment was carried
out under general anaesthetic. For RFA, under ultrasound
guidance a 6F sheath was introduced into the vein at an
appropriate point near or below the knee crease using
a Seldinger technique.14 The RFA applicator was passed
through the sheath and into the GSV under ultrasound
control. A laser sheath was inserted in a similar way for
patients undergoing EVLA. The RF catheter or laser sheath
was inserted and the tip positioned to approximately 2 cm
below the saphenofemoral junction or just distal to
a competent tributary of the GSV under ultrasound guid-
ance. For EVLA the BioLITEC (Biolitec AG, Germany) and for
RFA Olympus Celon RFiTT (Teltow,Germany) systems were
used.
Tumescence fluid (0.9% saline without local anaesthetic)
was injected into the saphenous compartment of all
patients who had EVLA (mean volume 467 ml). The laser
fibre was then inserted and the treatment commenced. The
laser fibre was inserted into the sheath after tumescence in
order to avoid inadvertent damage to the laser fibre by the
needle used to infiltrate fluid.15 The Biolitec Laser gener-
ator was used to provide laser energy (810 nm emission
wavelength). Pullback rates were set in order to deliver at
least 80 J/cm of energy to the vein.
In patients undergoing RFA tumescent fluid infiltration
was not used routinely. However in 11 limbs the vein was
less than 1 cm from the skin. Saline was infiltrated subcu-
taneously in these patients to reduce the risk of skin burn
(mean volume 52 ml). An Esmarch bandage was used to
compress the limb during treatment. The generator was set
to deliver a power of 23 W. The RFA catheter withdrawn at
approximately 0.8 cm per second during treatment using
audio feedback provided by the RFiTT system. Treatment
stopped when the catheter entered the sheath so the vein
containing the sheath was not treated.
Immediately following treatment of the GSV with RFA
and EVLA, intraoperative ultrasound imaging was used to
confirm shrinkage of the vein and to identify an increase in
echogenicity of the vein wall. Varices were treated by
phlebectomy under the same anaesthetic.
The time taken to complete each phase of the treatment
was recorded including the time taken to cannulate, posi-
tion the catheter, inject tumescent fluid, and complete the
endovenous procedure. A record was made of length of vein
treated and the number of avulsions above and below the
knee. All patients received a standard postoperative
regimen; dressings were placed over the wounds and crepe
bandages wrapped around both legs. Patients were
instructed to remove all dressings on the first postoperative
day, to shower and then to apply class II full length
compression hosiery for 2 weeks. Patients were asked to
complete post-operative assessment data sheets for 14
days assessing for pain, bruising, return to activity and any
248 S.D. Goode et al.analgesia taken. A 10 cm visual analogue scale (VAS) was
used for self-assessment of pain and bruising with patients
filling out a VAS for each leg treated. Scores were measured
in centimetres. Patients were asked to remove the stock-
ings on a daily basis to evaluate bruising. They were asked
to return to normal activity as soon as they wished and
return to activity VAS was scored as to how inactive
patients were on scale of 1e10.
Duplex ultrasound scans were repeated seven to four-
teen days after the operation looking for successful treat-
ment and whether there was any residual flow in the GSV.
The technologist performing the scan was not aware of the
treatment allocation of any limb in the study. Patients
returned to the clinic at least 6 months later. A second
post-operative duplex scan was performed and patients
completed a further AVVQ. Further follow-up is planned
after 2 and 5 years to assess the long term outcome.
Statistical analysis
Statistical calculations were performed using the Statistical
Package for Social Sciences (SPSS version 15.0; SPSS, Chi-
cago, IL) software. The distribution of the demographic
data was assessed and then analysed using the Student’s t
tests and ManneWhitney U tests for parametric and
nonparametric data respectively. Normally distributed data
were expressed as mean and SD and non normally distrib-
uted data were expressed as median and interquartile
range for the purposes of this study. Analysis of the pain
and bruising scores was performed using repeated measures
design for the bilateral cohort including length of vein as
covariate supervised by statistician. For the unilateral
cohort a univariate analysis was performed including length
of vein as a covariate. A P value of less than 0.05 was
considered significant and a VAS score of less than one was
considered normal.
Pre-calculation of sample size
A sample size of 20 for the BLARA study and 40 for the
ULARA study had been calculated based on the assumption
that there would be a 50% difference between the mean
pain score for both procedures, with significance at the 5%
level and a 90% power.
Results
The flow of patients through the two parts of this study are
shown in the CONSORT diagram (Fig. 1). One-hundred and
thirty five patients were considered for entry into the
study. From this group 66 patients were included in
the studies or a total of 87 legs. Twenty-one patients in the
BLARA study and 45 patients in the ULARA study. The details
of patients included in the BLARA cohort is summarised in
Table 1. Table 2 summarises the details of patients from the
ULARA cohort.
A greater length of vein was treated in the EVLA limbs
than in the RFA limbs. The median dose per cm was 91.4 J/
cm in the EVLA group. RFA was quicker to perform. The
median pullback rate was 0.5 cm/s. A similar number of
avulsions were performed in the RFA and EVLA limbs.Pain and bruising
In patients in the BLARA cohort, pain caused by RFA was
lower than that caused by EVLA . The peak pain score was
day 1 for RFA and day 5 for EVLA. Pain scores were signifi-
cantly different on days 2e11, with RFA being less painful
than EVLA (Fig. 2). The bruising score for RFA was lower
than that of EVLA, being significant on days 3, and 5e9
(Fig. 3). The peak score for RFA was day 3 and for EVLA day
5. In the ULARA cohort peak pain score for both RFA and
EVLA was on day 1. Both the bruising and the pain scores
were similar in the RFA and EVLA groups during the post-
operative period (Fig. 4).
Quality of life
In the BLARA cohort out of 17 patients who had bilateral
treatments 14 completed questionnaires were returned.
There was no statistical differences on preoperative AVVSS
scores between legs randomised to receive EVLA(14
patients, right leg 6 and left leg 8, mean AVVSS 3.95) and
legs randomised to receive RFA(14 patients, right leg 8 and
left leg 6, mean 3.99; PZ 0.96). In the patients who
completed AVVSS questionnaires 6 months after their
surgery, there was no statistically significant difference in
AVVSS between patients who had EVLA (mean 3.78) and
those who had RFA (mean 3.55; PZ 0.74).
Return to activity
Assessment of return to normal activity following treatment
with EVLA or RFA was only possible in patients from the
ULARA cohort. There were no statistical significant differ-
ences between the two treatments (Fig. 5).
Postoperative scans
The results of post-operative ultrasound imaging are sum-
marised in Table 3. 96% of patients returned at a median of
10 days after treatment for their first scan and 79% of
paitents returned a median of 237 days postoperatively for
the second scan. Similar rates of occlusion were observed in
the EVLA and RFA groups.
Complications
Two patients developed phlebectomy wound inflammation
which was treated with antibiotics by their primary care
physician. The cause of inflammation was not established.
One patient developed a transient area of numbness caused
by a phlebectomy. There were no long term complications.
Discussion
This study showed that resistive RFA of the GSV using the
CELON RFiTT system caused less pain and bruising in the
postoperative period than EVLA using the Biolitec 810 nm
Laser. The study was designed so that patients and
observers were blinded to the assigned treatment. Only the
surgeons knew how limbs had been treated and they were
not responsible for outcome assessment. In the bilateral
135 patients were considered for entry 
into the study 
33 patients with 
bilateral disease
21 were recruited to 
the study 
3 had bilateral RFA 
under GA 
2 had LA RFA
7 patients were 
recruited into another 
study looking at RFA 
7 had SSV disease and 35 did not
require treatment of GSV. Further
excluded patients did not meet entry
criteria 
17 patient took part
in BLARA study 2 excluded from primaryanalysis as failed to
return VAS scores 
2 excluded for protocol 
violation
BLARA Study 
56 patients with 
unilateral disease 
ULARA Study 
45 were recruited to 
the study 
1 closure fast 
4 foam 
6 stripping
23 RFA 22 EVLA
19 patients 
analysed 
17 patients 
analysed 
Figure 1 The CONSORT diagram for the BLARA and ULARA studies.
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were therefore able to make objective comparisons with
respect to levels of pain and bruising for each different
treatment modality. This type of study design where
patients act as their own ‘controls’ has been reported
previously.5
This was a small study conducted by one surgeon in
a single institution. The results are supported by a larger
multicentre study. The difference between the study
designs is that the multicentre study compared segmentalTable 1 Demographic and treatment details of patients in BLA
Laser
Age 47  12
Sex
Male 2
Female 15
Cannulation time (min)a 1 (IQR 1e2.75)
Positioning time (min) 3.8 2.6
Volume tumescence (ml)a 467 (IQR 412e550
Tumescence time (min) 7.4 2.1
Length of procedure (min)a 4.5 (IQR 3.25e5)
Lower leg avulsions 7 5
Upper leg avulsionsa 1 (IQR 0e2.75)
Total no avulsions 14 7
Time for avulsions (min) 15 9
Length of vein treated (cm)a 46 (IQR 44e49)
Diameter of vein (cm) 7.5 2.5
Joules/cm for EVLA 91.4
a Data were not normally distributed and therefore nonparametric
icance values were calculated using a paired t test.conductive, rather than resistive radiofrequency ablation,
with EVLA using 980 nm laser.16
Several other studies have been performed to assess
pain and bruising following RFA and EVLA treatments. The
results of these studies also support our findings, when
EVLA treatment bruise scores ranged from 1.3 to 46% and
significant postoperative pain was experienced by 3.9e67%
of patients.17,18 This compares with only 10.8% of patients
experiencing limb pain on day 3 in a recent series of 194
patients treated with RFA.16 In the same study 6.4% ofRA cohort.
RF P value
47  11 1
2 1
15
1 (IQR 1e3.75) 0.615
3 1.7 0.338
) 52 (IQR 0-100) 0.0001
1.9 1.3 0.0001
2 (IQR 2e3) 0.0001
9 5 0.255
0 (IQR 0e6.75) 0.822
15 6 0.493
19 7 0.341
37 (IQR 31e43) 0.0001
8.1 2.6 0.51
N/A
statistic test was used e Mann Whitney U test. Remaining signif-
Table 2 Demographic and treatment details of patients in ULARA cohort.
LASER RF P value
Age 48 11.6 45 9.3 0.38
Sex
Male 7 8 0.513
Female 15 15
Positioning time (min) 2 0.8 3 1 0.83
Tumescence time (min) 8.7 3.4 6 2 0.32
Lower leg avulsions 10 7 8 3.5 0.75
Total no avulsions 13 8.3 10 1.3 0.51
Time for avulsions (min) 11 5.6 13 6 0.70
Length of vein treated (cm)a 44 (IQR 39e48) 35 (IQR 33e39) 0.286
Diameter of vein (cm) 11 2.3 8.5 2.5 0.09
Joules/cm for EVLA 92.67 20 n/a n/a
a Data were not normally distributed and therefore nonparametric statistic test was used e Mann Whitney U test. Remaining signif-
icance values were calculated using a paired t-test.
250 S.D. Goode et al.patients suffered bruising whilst only 1.6% had ultrasound
proven haematoma. A recent publication by Almeida et al
showed less pain and improved QOL following RF versus
EVLA treatment in a randomised trial.19
Our findings may be explained by differences in the
mechanism of action of RFA and EVLA to deliver energy to
the vein wall.16 The generally accepted mechanisms of
action of endovenous thermal treatment of varicose veins is
by protein denaturation and destruction of cell structure
which ultimately leads to collagen contraction,20,21
confirmed by histological studies.22,23 Another mechanism
that has been proposed is that EVLA causes permanent vein
closure through a high-temperature photothermolytic
process at the point of contact between the vein and the
laser.24 Schmedt et al.25 showed that endovenous treat-
ment with RFA resulted histologically in reproducible and
complete circular thermal alteration of vein wall. When
they looked at vein wall alteration following EVLA they
found changes ranging from localised tissue ablation in
certain quadrants of vein wall up to complete transmural
ablation and multiple perforations. The extent of veinFigure 2 The mean pain scores (error bars: standard deviaperforation caused by EVLA may account for the increased
pain and bruising experienced by patients.
The vascular technologists who performed the preoper-
ative and postoperative duplex scans were blinded to the
treatments assigned to each limb. Differences in the
appearance of vein segments treated by RFA and EVLA were
apparent at the time of the first postoperative duplex scan.
The veins treated with RFA tended to be small in diameter
whilst those treated with EVLA were large and had evidence
of oedema, vein wall perforations and large amounts of
haematoma in the soft tissues. These observations in
‘paired’ limbs may further support the view that higher
levels of pain and bruising observed in limbs treated with
EVLA are due to thermal damage of perivenous tissues and
vein perforation. Previous studies have also demonstrated
a higher incidence of painful thrombophlebitis with EVLA
which may again explain the higher pain scores observed for
EVLA in the presented study.26,27
For those included in the BLARA cohort, it could be
argued that bilateral treatments might lead to unreliable
assessments of pain due to distracting painful stimuli fromtion) for each treatment over the 2-week study period.
Figure 3 The mean bruising scores (error bars: standard deviation) for each treatment over the 2-week study period.
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theory of pain.28 However, this strategy showed clearly that
the EVLA group was scored as more painful than the RFA
limb. Interestingly in unilateral patients there was no
difference between RFA and EVLA patients. This may have
been because the sample size was too small to demonstrate
this small difference.
The length of vein treated was longer in the EVLA legs
and it is possible that this might be the reason for higher
pain scores in that group. The reason for a difference in
treatment lengths was the Laser treated the GSV to the
point of entry while the RF treated the GSV to the tip of the
indwelling sheath. Once withdrawn into the sheath,
the applicator was not in contact with the vein wall and
there was no treatment. This was a technique used to
reduce the risk of skin damage and to allow repeated
passage of the RF applicator if required. Since the studyFigure 4 The mean pain scores (error bars: standard deviation
BLARA(B) and ULARA(U) studies.was finished, the senior author now removes the sheath and
treats the GSV to the point of entry. The reported pain
scores in subsequent patients treated with RFA have
remained the same as those in this study so it is unlikely
that the length of vein treated affected the pain score.
More recent work has shown that the use of wavelengths
longer than 810 nm laser result in less post-operative
pain.29 Our study used the standard wavelength available
when the trial commenced (810 nm). We acknowledge that
there may be advantages in using newer lasers operating at
longer wavelengths.
Patients in this study underwent phlebectomy for varices
associatedwith truncal saphenous incompetence in the same
session as saphenous ablation. Therewas nodifference in the
number of phlebectomies performed between EVLA and RFA
limbs in the number of phlebectomies performed, so this will
not have influenced the outcome of this study.) for each treatment over the 2-week study period for both
Figure 5 The mean inactivity scores (error bars: standard
deviation) for each treatment over the 2-week study period for
the ULARA study.
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operative duplex ultrasound 1 week post-operatively was
95%. These results are similar to rates reported for imme-
diate postoperative occlusion in other studies.7,21,26,30 A
recent meta-analysis of EVLA reported occlusion rates
ranging from 87.9-100%.31 At 6 months follow up we found
little difference between the 2 techniques, however only
a small number of patients returned for their second scan.
The actual occlusion rates were a little disappointing. The
senior author was experienced in endovenous ablation and
the effects of a learning curve are unlikely to have affected
the results. All the EVLA procedures used a LEED of 80 J/cm
of energy or more to minimise recanalisation. It is not clear
why the observed success rate of EVLA was lower than more
recent studies. Previous non-randomised studies have
demonstrated slightly higher efficacy of EVLA compared
with RFA in terms of immediate treatment success and also
less recanalisation at follow up.32,33 The 74% 6-month
occlusion rate of veins treated with RFA in our study might
be related to the energy delivered through the vein wall. At
the time of the study, the manufacturers had suggested
a generator setting of between 20 and 25 W following
previous successful pilot studies. A pullback rate of 1 cm/s
would give a LEED of about 25 J/cm for RFA, however the
mechanism of transmural resistive heating requires less
energy to produce heating to 80 C than a laser does to heat
tissue to several hundred centigrade. Our practice has been
revised since this study; power is now set to 10e18 W with
a pullback rate of 0.5 cm/s resulting in occlusion rates of
98%. We no longer use an Esmarch bandage and employ
tumescent infiltration in all patients.
In conclusion, this study showed that RFA produced less
pain and bruising than EVLA using an 810 nm Biolitec
system. Success of treatment, quality of life and return to
activity were not affected by treatment modality.Table 3 Summary of occlusion rates.
Post op duplex LASER RF
10 Days 95% (37/39) 95% (38/40)
9 Month 78% (25/32) 74% (25/34)Conflict of Interest
None.
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